Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

2,450

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

2,450 results for “CD4 T cells”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patient

ClinicalTrials.gov study NCT06659068. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad32/100

RNAseq of tolerized auroreactive RBC-specific CD4 T cells, HODxOTII murine model of autoimmune hemolytic anemia (AIHA)

Open the record for dataset details and reuse information.

publicJul 2024View details →
dryad32/100

Timing of blood sample processing affects the transcriptomic and epigenomic profiles in CD4+ T-cells of atopic subjects

Open the record for dataset details and reuse information.

publicOct 2022View details →
dryad28/100

Data from: Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function.

<p>Thymic regulatory T cells (tTreg) are potent inhibitors of autoreactive immune responses and loss of tTreg function results in fatal autoimmune disease.  Defects in Treg number or function are also implicated in multiple autoimmune diseases, leading to growing interest in use of Treg as cell therapies to establish immune tolerance.  Because tTreg are present at low numbers in circulating blood and may be challenging to purify and expand, and also inherently defective in some subjects, we designed an alternative strategy to creating autologous Treg-like cells from bulk CD4+ T cells.  We utilized homology-directed-repair (HDR)-based gene-editing to enforce FOXP3 expression.  Targeted insertion of a robust enhancer/promoter proximal to the first coding exon bypassed epigenetic silencing, permitting stable, high level endogenous FOXP3 expression.  HDR-edited T cells, edTreg, manifested a transcriptional program leading to sustained expression of canonical markers and suppressive activity of tTreg.  Both human and murine edTreg mediated immunosuppression in vivo in models of inflammatory disease.  Further, this engineering strategy permitted generation of antigen-specific edTreg with robust in vitro and in vivo functional activity.  Finally, edTreg could be enriched and expanded at scale using clinically-relevant methods.  Together, these finding suggest edTreg production may permit broad future clinical application.</p>

opencc-zeroMay 2020View details →
zenodo28/100

Figure 2 from: Hartati FK, Nafisah W, Sutanto A, Saati EA, Khairoh M, Sjamsiah (2024) Aqueous black rice (Oryza sativa L. indica) extract enhanced the activation of CD4+ and CD8+ T cells in mouse breast cancer model. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e113442

Figure 2 Aqueous black rice (ABR) extract reduced the relative number of CD4+IL17+, CD4+TNFα+, and CD4+IFNγ+ cytokine production. A, C, E. were flow cytometry diagram; B, D, F. were the graph of flow cytometry results. The bar in the graph shows the calculation results as the mean ± SD of the relative number of cytokine production. *P&lt;0.05, indicate significant different. The group in this study were normal group; Cancer, DMBA 15 mg/kg BW; Cis, DMBA 15 mg/kg BW + Cisplatin 5 mg/kg BW; ABR1, DMBA 15 mg/kg BW + aqueous black rice extract 0.2 g/kg BW; ABR2, DMBA 15 mg/kg BW + aqueous black rice extract 0.3 g/kg BW; ABR3, DMBA 15 mg/kg BW + aqueous black rice extract 0.4 g/kg BW; ABR4, DMBA 15 mg/kg BW + aqueous black rice extract 0.5 g/kg BW.

opencc-by-4.0Feb 2024View details →
zenodo28/100

Figure 1 from: Hartati FK, Nafisah W, Sutanto A, Saati EA, Khairoh M, Sjamsiah (2024) Aqueous black rice (Oryza sativa L. indica) extract enhanced the activation of CD4+ and CD8+ T cells in mouse breast cancer model. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e113442

Figure 1 Aqueous black rice (ABR) extract increased the relative number of CD4+CD62L- cells and CD8+CD62L- cells. A, C. Show flow cytometry diagrams, and B, D. Show graphs of the flow cytometry results. The bars in the graphs show the calculated results as the mean ± SD of the relative number of CD4+ and CD8+ cell activations. *P&lt;0.05 indicates a significant difference. The groups in this study included the following groups: Normal; Cancer, DMBA 15 mg/kg BW; Cis, DMBA 15 mg/kg BW + Cisplatin 5 mg/kg BW; ABR1, DMBA 15 mg/kg BW + ABR extract 0.2 g/kg BW; ABR2, DMBA 15 mg/kg BW + ABR extract 0.3 g/kg BW; ABR3, DMBA 15 mg/kg BW + ABR extract 0.4 g/kg BW; and ABR4, DMBA 15 mg/kg BW + ABR extract 0.5 g/kg BW.

opencc-by-4.0Feb 2024View details →
zenodo28/100

Figure 3 from: Hartati FK, Nafisah W, Sutanto A, Saati EA, Khairoh M, Sjamsiah (2024) Aqueous black rice (Oryza sativa L. indica) extract enhanced the activation of CD4+ and CD8+ T cells in mouse breast cancer model. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e113442

Figure 3 Aqueous black rice (ABR) extract effect on mammary mice histology based on Hematoxylin &amp; Eosin staining (M: 400x). D, ductal; AT, adipose tissue; arrow, cancer cell. The group in this study were normal group; Cancer, DMBA 15 mg/kg BW; Cis, DMBA 15 mg/kg BW + Cisplatin 5 mg/kg BW; ABR1, DMBA 15 mg/kg BW + aqueous black rice extract 0.2 g/kg BW; ABR2, DMBA 15 mg/kg BW + aqueous black rice extract 0.3 g/kg BW; ABR3, DMBA 15 mg/kg BW + aqueous black rice extract 0.4 g/kg BW; ABR4, DMBA 15 mg/kg BW + aqueous black rice extract 0.5 g/kg BW.

opencc-by-4.0Feb 2024View details →
zenodo28/100

Raw data to: "Vaccine-elicited CD4 T cells prevent the deletion of antiviral B cells in chronic infection"

<p>Raw data underlying the publication by Narr et al. entitled &quot;Vaccine-elicited CD4 T cells prevent the deletion of antiviral B cells in chronic infection&quot;.</p>

opencc-by-4.0Nov 2021View details →
zenodo28/100

Phosphoproteomics analysis of antibody-based stimulation of TCR in CD4+ T cells

<p>Code associated with the paper &quot;LymphoAtlas: a dynamic and integrated phosphoproteomic resource of TCR signaling in primary T cells reveals ITSN2 as a regulator of effector functions&quot; published in Molecular Systems Biology&nbsp;in 2020.</p> <p>abstract:&nbsp;<br> T-cell receptor (TCR) ligation-mediated protein phosphorylation regulates the activation, cellular responses, and fates of T cells. Here, we used time-resolved high-resolution phosphoproteomics to identify, quantify, and characterize the phosphorylation dynamics of thousands of phosphorylation sites in primary T cells during the first 10&nbsp;min after TCR stimulation. Bioinformatic analysis of the data revealed a coherent orchestration of biological processes underlying T-cell activation. In particular, functional modules associated with cytoskeletal remodeling, transcription, translation, and metabolic processes were mobilized within seconds after TCR engagement. Among proteins whose phosphorylation was regulated by TCR stimulation, we demonstrated, using a fast-track gene inactivation approach in primary lymphocytes, that the ITSN2 adaptor protein regulated T-cell effector functions. This resource, called LymphoAtlas, represents an integrated pipeline to further decipher the organization of the signaling network encoding T-cell&nbsp;activation. LymphoAtlas is accessible to the community at:&nbsp;<a href="https://bmm-lab.github.io/LymphoAtlas">https://bmm-lab.github.io/LymphoAtlas</a>.</p>

openbsd-2-clause-netbsdMay 2022View details →
ClinicalTrials.gov28/100

COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells

ClinicalTrials.gov study NCT04402892. IPD Sharing: NO. Countries: 0. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 40

ClinicalTrials.gov study NCT00000649. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

ClinicalTrials.gov study NCT00877656. IPD Sharing: Not stated. Countries: 0. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Autologous CD4 T-Cells in HIV (C34-CXCR4)

ClinicalTrials.gov study NCT03020524. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

ClinicalTrials.gov study NCT00925756. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure

ClinicalTrials.gov study NCT06889142. IPD Sharing: NO. Countries: 0. Publications: 11.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

ClinicalTrials.gov study NCT01777997. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

ClinicalTrials.gov study NCT00000908. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100

ClinicalTrials.gov study NCT00385957. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

ClinicalTrials.gov study NCT01969058. IPD Sharing: Not stated. Countries: 2. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad28/100

Data from: Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function.

Open the record for dataset details and reuse information.

publicMay 2020View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record